Does Security Health Plan Cover Metformin?

Metformin hydrochloride (brand names Glucophage and Glucophage XR; generic immediate-release and extended-release tablets) is a biguanide oral antidiabetic agent, FDA-approved for type 2 diabetes mellitus in adults and in children 10 and older. Security Health Plan of Wisconsin is a regional nonprofit insurer offering commercial, ACA marketplace, Medicare Advantage, and employer group plans in Wisconsin.

The short answer: across nearly every U.S. commercial and Medicare Advantage formulary, generic immediate-release metformin is placed in the lowest cost-sharing tier because it is inexpensive, has been generic since the 1990s, and is the guideline-recommended first-line agent for type 2 diabetes. That pattern is highly likely to hold for Security Health Plan as well, but this article cannot verify Security Health Plan's current tier list, copay amount, or prior authorization rules for your specific plan year, because no Security Health Plan formulary document was available as a source. Confirming your own plan's terms takes a short call or portal check, described below.

The one paragraph you can rely on

Generic immediate-release metformin is FDA-approved for type 2 diabetes and, industry-wide, is almost universally placed on the lowest ("preferred generic") tier of commercial and Medicare Part D formularies because it is off-patent, inexpensive, and recommended as first-line pharmacologic therapy for type 2 diabetes by the American Diabetes Association's Standards of Care. Extended-release and brand-name versions (Glucophage XR, Fortamet, Glumetza) are more often placed on a higher tier or subject to step therapy. Whether Security Health Plan specifically places generic metformin on Tier 1, and what your exact copay is, depends on your plan year and benefit design and must be confirmed through Security Health Plan directly, since insurer-specific formulary documents were not part of the source material for this article.

What is established versus what needs verification

Established (stable, not insurer-specific):

• Metformin's FDA-approved indication is type 2 diabetes mellitus in adults and pediatric patients 10 and older. Verification of current label details: FDA metformin label.
• The American Diabetes Association's Standards of Care describe metformin as the preferred initial pharmacologic agent for type 2 diabetes, absent contraindication or intolerance: ADA Standards of Care, pharmacologic approaches.
• Metformin is contraindicated at an eGFR below 30 mL/min/1.73 m2, with caution and dose consideration between 30 and 45, per current FDA labeling.
• Federal ACA rules and Medicare Part D rules give members internal appeal rights and, after internal appeals are exhausted, access to independent external review. The specific timelines and forms are administered at the state and plan level.
• Medicare Part D restructured out-of-pocket costs under the Inflation Reduction Act; general program information is at CMS's Part D overview. The exact dollar figure for any given year should be confirmed against the current CMS guidance rather than assumed from a prior year's article.
• Wisconsin's Medicaid expansion program, BadgerCare Plus, maintains a preferred drug list; whether and at what copay generic metformin sits on that list currently should be checked directly with Wisconsin DHS rather than assumed from this article, since preferred drug lists change.

Plausible but not confirmed for Security Health Plan specifically:

• That generic metformin IR sits at Tier 1 on Security Health Plan's current commercial and Medicare Advantage formularies. This is the industry norm, but no Security Health Plan-specific formulary document was available to confirm it for the current plan year.
• Specific copay ranges (for example, a low single-digit or low double-digit dollar range per 30-day fill). Copay structures vary by specific plan, employer group, and year, and no Security Health Plan cost-sharing schedule was available to source these numbers.
• Whether prior authorization applies to extended-release or brand formulations under Security Health Plan's current rules, and what step-therapy documentation it requires.
• Whether and how Security Health Plan covers off-label use (prediabetes, PCOS) and under what diagnosis coding.

Not established from any source used here:

• Any dollar figure for a specific Security Health Plan copay, deductible interaction, or coinsurance percentage.
• Coverage of metformin for longevity or anti-aging use. No U.S. insurer, including Security Health Plan, is known to cover a drug for an indication without a recognized diagnosis code, and "longevity optimization" is not a billable diagnosis. This is a reasonable inference from how pharmacy benefit adjudication works generically, not a claim sourced to Security Health Plan policy.

Why metformin is a first-line, inexpensive, well-established drug

Metformin has been generic and widely manufactured for decades, and it is the first-line pharmacologic agent recommended in ADA Standards of Care for adults with type 2 diabetes who do not have a contraindication. Two of the historic trials often cited in support of metformin's cardiovascular and diabetes-prevention benefit are the UK Prospective Diabetes Study (UKPDS) and the Diabetes Prevention Program (DPP), both large, government- or foundation-funded randomized trials from the 1990s and early 2000s. Because this draft's inherited citation identifiers for those trials could not be independently verified against the primary literature, the specific numeric effect sizes are not restated here as sourced facts; an editor should confirm the exact trial results against the primary publications (UKPDS in The Lancet, 1998; DPP in the New England Journal of Medicine, 2002) before publishing any specific percentage.

Metformin has also drawn interest as a possible longevity-related agent, most visibly through the TAME (Targeting Aging with Metformin) trial concept, which as far as publicly reported has aimed to test whether metformin delays onset of age-related chronic disease in older adults. This is trial-stage, hypothesis-testing evidence, not an approved indication, and it has no bearing on current insurance coverage.

Similarly, metformin's use in polycystic ovary syndrome (PCOS) is a recognized off-label practice supported by endocrine society guidance, but the exact 2023 international PCOS guideline citation inherited in this draft could not be verified here and should be checked by an editor against the current Endocrine Society or ESHRE/ASRM guideline text before it is cited as a specific source.

Covered indication versus off-label use: what determines a payer's decision

Insurers, including Security Health Plan, generally cover a prescription when it matches the FDA-approved indication (type 2 diabetes for metformin) or a recognized off-label use supported by drug compendia that the insurer's utilization management team consults. For metformin, the FDA-approved use is type 2 diabetes. Off-label uses that clinicians commonly prescribe metformin for include PCOS and prediabetes; whether a specific payer covers those uses depends on the payer's own medical policy, not on national averages, and can differ between plan types within the same insurer.

If your prescription is for an off-label use, the prescriber's documentation (correct ICD-10 diagnosis code, relevant lab values, and citation of a recognized guideline) is usually what determines whether a claim clears automatically or triggers prior authorization. This is true across payers generally; it is not a Security Health Plan-specific rule confirmed here.

Prior authorization: general pattern and what to expect

Immediate-release generic metformin prescribed for type 2 diabetes at standard doses rarely triggers prior authorization at any major U.S. insurer, because it is inexpensive and guideline-first-line. Prior authorization becomes more likely when:

• The prescription is for a brand-name or extended-release formulation rather than generic immediate-release.
• The dose is above the standard FDA-labeled range.
• The indication is off-label (prediabetes, PCOS) without clear diagnostic documentation.

Standard turnaround times, appeal windows, and expedited-review timeframes are governed by a mix of federal ACA rules and state insurance regulation. Wisconsin has its own Office of the Commissioner of Insurance process for external review once internal appeals are exhausted, but the specific statutory citation and time windows should be verified against the current Wisconsin OCI guidance rather than assumed, since regulatory citations inherited into this draft could not be independently confirmed.

Cost if coverage does not apply or before you meet a deductible

Metformin's generic formulation ranks among the most affordable prescription medications available in the United States. Many retailers offer it through affordable programs including chain store generic lists, no-membership discount cards, and online pharmacy services. Since pricing through these programs fluctuates regularly and cannot be independently confirmed, we have not included specific costs as established facts. When seeking metformin, check with your pharmacist about the current cash price if you face a deductible or your insurance excludes your needed formulation, then compare this to any available discount card pricing before using your insurance; discount cards and insurance cannot typically be used together on a single prescription, so you would choose whichever option costs less on that particular day.

Safety and monitoring relevant to coverage documentation

Metformin carries an FDA labeling contraindication at eGFR below 30 mL/min/1.73 m2, with caution advised between 30 and 45. Because payers often reference FDA labeling in medical necessity review, a recent renal function panel in the chart can support a prior authorization request, particularly for older adults or those with known kidney disease. Long-term metformin use is also associated with reduced vitamin B12 levels, and periodic B12 monitoring is a reasonable clinical practice for patients on long-term therapy, particularly those with neuropathy symptoms or unexplained anemia; this is a clinical judgment for your prescriber, not something this article can individualize for you.

None of this substitutes for your prescriber's dosing decision. Anyone with symptoms of lactic acidosis (unusual muscle pain, difficulty breathing, unusual sleepiness, or abdominal pain while on metformin, especially around illness, dehydration, or contrast imaging) should seek urgent medical care rather than waiting on a coverage question.

Verification checklist: stable facts versus facts that expire

Use this before assuming anything in this article, or any general metformin coverage article, applies to your specific situation.

Stable, federal or clinical facts (safe to treat as durable, but still confirm the source date):

• Metformin's FDA-approved indication (type 2 diabetes; pediatric 10+), check the current label at [FDA/DailyMed] rather than an old PDF if precision matters.
• The eGFR-based contraindication and caution thresholds in the current FDA label.
• ADA's general first-line recommendation for metformin in type 2 diabetes, from the current year's Standards of Care.
• The general structure of ACA internal/external appeal rights (these exist federally, even though exact timelines vary by state and plan).

Date-sensitive, insurer- or state-specific facts (verify fresh, every time, before relying on them):

• Security Health Plan's current formulary tier for generic metformin IR, ER, and brand versions.
• Your specific plan's copay, coinsurance, and whether a drug deductible applies before the copay kicks in.
• Whether prior authorization or step therapy is currently required for ER or brand formulations under your plan.
• Security Health Plan's current medical policy on off-label coverage for prediabetes or PCOS, and what diagnosis coding it requires.
• The current BadgerCare Plus Preferred Drug List placement and copay for metformin, if that applies to you.
• The current Medicare Part D initial coverage limit and out-of-pocket cap for the plan year you are in.
• Any specific retail or discount cash price for metformin, since these promotions and price lists change without notice.

How to close the gap quickly:

1. Log into the Security Health Plan member portal and use the plan-specific drug cost tool, entering your plan's name or ID, not just "Security Health Plan" generically.
2. Call the member services number on your card and ask for the tier, copay, and PA status for generic metformin at your dose and formulation, and get the representative's name and the date of the call.
3. Have your prescriber's office run a real-time benefit check at the point of prescribing so any PA requirement surfaces before you go to the pharmacy.
4. If you are denied, ask for the denial reason in writing immediately; that document controls your appeal timeline.

Common reader questions

Is generic metformin likely to be covered by Security Health Plan? Yes, in the sense that industry-wide, generic immediate-release metformin is almost always placed on an insurer's lowest cost-sharing tier because of its cost and first-line guideline status. This article cannot confirm Security Health Plan's exact current tier or copay because no Security Health Plan formulary document was available as a source; verify directly through the member portal or member services line.

Does metformin need prior authorization? Generally not for generic immediate-release metformin at standard doses for type 2 diabetes, across most U.S. insurers. Extended-release brand versions, off-label indications, or above-label doses are more likely to trigger a PA requirement. Confirm your plan's current rule before assuming either way.

Is metformin covered for prediabetes or PCOS? These are off-label uses relative to metformin's FDA-approved indication. Coverage for off-label use depends on the payer's own medical policy and the strength of the prescriber's documentation (diagnosis code, labs, guideline citation). Some plans cover it readily; others require a type 2 diabetes diagnosis. This varies enough between plans that a general answer is not reliable, and it should be confirmed with Security Health Plan directly.

What if my claim is denied? Federal ACA rules generally guarantee an internal appeal, and Wisconsin has a state process for independent external review after internal appeals are exhausted. The exact deadlines and forms should come from your denial letter and Security Health Plan's own appeal instructions, since the specific statutory citations and time windows were not independently verifiable for this article.

Does Security Health Plan cover metformin for longevity or anti-aging use? There is no FDA-approved or generally recognized diagnosis code for "longevity" or "anti-aging" use, and insurers adjudicate claims against a diagnosis. It is reasonable to expect that a longevity-only prescription would not be covered by Security Health Plan or any mainstream U.S. insurer, though this is an inference from how coverage generally works rather than a Security Health Plan policy statement sourced directly for this article.

References

1. American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes, Section 9: Pharmacologic Approaches to Glycemic Treatment. https://diabetesjournals.org/care/article/47/Supplement_1/S158/153962/9-Pharmacologic-Approaches-to-Glycemic-Treatment

2. U.S. Food and Drug Administration. Metformin Hydrochloride Tablets prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020357s037s039,021202s021s023lbl.pdf

3. Centers for Medicare and Medicaid Services. Medicare Prescription Drug Coverage, general program information. https://www.cms.gov/medicare/prescription-drug-coverage/prescriptiondrugcovgenin

Editor note: The original version referenced specific studies and sources (UKPDS 34, the Diabetes Prevention Program, a 2023 PCOS guideline, a Montori quotation, and the Barzilai/TAME research) with links to PubMed and academic.oup.com. During this revision, these references could not be independently confirmed against their original sources and have therefore been either removed or replaced with general descriptions without links, marked with a verification flag. Prior to final publication, please verify each reference directly against its primary source material and reintroduce only those citations and specific figures that you have personally confirmed. The Montori quotation attribution was removed because we could not locate the original statement it claimed to reference.